Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (487)	1/27/2003 4:15:19 AM
From: nigel bates	Respond to of 1022

CRXL out of the mAB business Message 18495186

To: Icebrg who wrote (487)	2/3/2003 7:01:15 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

Abgenix and Chugai Collaborate to Develop and Manufacture Antibody Therapeutics Message 18527450 It seems as if Abgenix got a good partner here. Apart from that, these types of deals demonstrates how focus is shifted towards targeting and away from the method for the development of the mAbs. One would have thought that Abgenix through their extensive target-harvesting collaborations with among others Curagen and Lexicon would not have to travel to Japan to find promising new anti-body targets to work on.